leisure time -WSS

leisure time

author：hotspot 2025-10-02 21:04:33 - browse：2113

President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ADCs take center stage as promising cancer treatments

WSS

Bird flu reported in person exposed to presumably infected cattle

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Health tech investors get more selective as pandemic boom fades

CZI to create biohub to build anti

FDA clears Verve to begin U.S. study of gene

Medicare Advantage 2025 payments will dip, Biden administration says

focus

leisure time

hotspot

Alkermes shareholders re

Study on Amgen’s bispecific immunotherapy produces positive data

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Apple is now the first public company to be valued at $3 trillion

Gut bacteria may contribute to kidney autoimmunity, study finds

State Dept. review finds Biden bears some blame for Afghanistan failures

Florida Supreme Court upholds state's abortion ban

Bright Health sells Medicare Advantage business to Molina

Oral obesity drug from Viking Therapeutics hits key early target

leisure time

U.K. decision on ALS drug has neurologists, advocates up in arms

Results on Novartis prostate cancer therapy could expand its use

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Roivant's CEO is a star, but biotech's black hole persists

First Opinion on colorectal cancer screening: letter and response

Alzheimer's risk factor APOE4 may be a distinct form of the disease

hotspot

hotspot

entertainment

knowledge